MyCartis is an immuno-diagnostic solution provider assuring accurate, clinical guidance with its sample to answer Evalution® platform. MyCartis develops its own immuno-diagnostic menu for the clinical user and collaborates with partners to port assays on its platform. EVALUTION® leverages high quality analytical performance from conventional immunodiagnostic approaches with the unique capability to quantify and monitor binding reactions in real-time. This provides the user with novel, timely and hence highly actionable information. MyCartis primarily focuses on oncology and in particular immuno-oncology. One of the assays in development will monitor adverse events in cancer patients undergoing immuno-oncology treatment. In addition to the existing Evalution® RUO platform, MyCartis is developing a CE-IVD clinical configuration and has obtained its ISO13485 certification. Visit www.mycartis.net or contact MyCartis for more information: info@mycartis.net